Bekric, D.; Neureiter, D.; Ablinger, C.; Dobias, H.; Beyreis, M.; Ritter, M.; Jakab, M.; Bischof, J.; Koller, U.; Kiesslich, T.;
et al. Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer. Cancers 2023, 15, 1569.
https://doi.org/10.3390/cancers15051569
AMA Style
Bekric D, Neureiter D, Ablinger C, Dobias H, Beyreis M, Ritter M, Jakab M, Bischof J, Koller U, Kiesslich T,
et al. Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer. Cancers. 2023; 15(5):1569.
https://doi.org/10.3390/cancers15051569
Chicago/Turabian Style
Bekric, Dino, Daniel Neureiter, Celina Ablinger, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Martin Jakab, Johannes Bischof, Ulrich Koller, Tobias Kiesslich,
and et al. 2023. "Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer" Cancers 15, no. 5: 1569.
https://doi.org/10.3390/cancers15051569
APA Style
Bekric, D., Neureiter, D., Ablinger, C., Dobias, H., Beyreis, M., Ritter, M., Jakab, M., Bischof, J., Koller, U., Kiesslich, T., & Mayr, C.
(2023). Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer. Cancers, 15(5), 1569.
https://doi.org/10.3390/cancers15051569